Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses GOSS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GOSS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Faheem Hasnain | $649,649 | $0 | $0 | $1,392,006 | $254,800 | $0 | $4,000 | $2,300,455 |
| Chairman, President and Chief Executive Officer | ||||||||
| Bryan Giraudo | 519,830 | 0 | 0 | 576,688 | 152,913 | 0 | 4,000 | 1,253,431 |
| Chief Operating Officer and Chief Financial Officer | ||||||||
| Robert Smith | 463,500 | 75,000 | 0 | 517,031 | 121,213 | 0 | 4,000 | 1,180,744 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Faheem Hasnain | $2,300,455 | $2,005,432 | — | +295,023 |
| Bryan Giraudo | 1,253,431 | 1,171,904 | — | +81,527 |
| Robert Smith | 1,180,744 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John D. Quisel | Director | 2026-06-04 | A | 115,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Skye Drynan | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas O. Daniel | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven D. Nathan | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Russell Cox | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Milligan | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Robert Smith | OPTION | — | — | — | — | — | $517,031 |
| Bryan Giraudo | OPTION | — | — | — | — | — | 576,688 |
| Faheem Hasnain | OPTION | — | — | — | — | — | 1,392,006 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Robert Smith | $0 | $0 | $517,031 | 0.0% |
| Bryan Giraudo | 0 | 0 | 576,688 | 0.0% |
| Faheem Hasnain | 0 | 0 | 1,392,006 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bryan Giraudo | Option | 638,000 | 1.13 | — |
| Robert Smith | PSU | 162,500 | — | 503,750 |
| Faheem Hasnain | Option | 683,594 | 0.97 | — |
| Bryan Giraudo | Option | 66,094 | 1.21 | — |
| Faheem Hasnain | Option | 1,540,000 | 1.13 | — |
| Faheem Hasnain | Option | 209,636 | 0.84 | — |
| Faheem Hasnain | Option | 170,157 | 1.21 | — |
| Bryan Giraudo | Option | 283,204 | 0.97 | — |
| Faheem Hasnain | PSU | 437,500 | — | 1,356,250 |
| Robert Smith | Option | 750,000 | 0.97 | — |
| Bryan Giraudo | PSU | 181,250 | — | 561,875 |
| Faheem Hasnain | Option | 750,000 | 1.36 | — |
| Bryan Giraudo | Option | 86,850 | 0.84 | — |
| Robert Smith | Option | 572,000 | 1.13 | — |
| Robert Smith | Option | 487,500 | 0.97 | — |
The key objectives of our executive compensation program are: To attract, engage and retain an executive team who will provide leadership for our future success by providing competitive total pay opportunities. To establish a direct link between our business results, individual executive performance and total executive compensation. To align the interests of our named executive officers with those of our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 111,286,550 | 7,545,502 | 137,461 | 93.65% | Passed |
| 2025 | 2025-06-25 | 125,358,485 | 3,769,651 | 472,930 | 97.08% | Passed |
| 2024 | 2024-06-06 | 115,985,182 | 40,356,919 | 5,831,133 | 74.19% | Passed |
| 2023 | 2023-06-08 | 38,901,355 | 19,975,931 | 87,316 | 66.07% | Passed |
| 2022 | 2022-06-09 | 46,093,471 | 345,876 | 31,930 | 99.26% | Passed |
| 2021 | 2021-06-09 | 50,886,375 | 298,541 | 2,688,857 | 99.42% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 93.65%a |
| 2025 | 2025-06-25 | 97.08%b |
| 2024 | 2024-06-06 | 74.19%c |
a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, whether our stockholders have approved the compensation of the named executive officers, or whether our stockholders have approved the amendment and restatement our 2019 Incentive Award Plan.”.
c. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, or whether our stockholders have approved the compensation of the named executive officers.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas Daniel, M.DIndependent · Lead Independent Director · Compensation · Nominating/Governance | $76,875 | $0 | $122,694 | — | $0 | $199,569 |
| Russell CoxIndependent · Audit · Compensation (Chair) | 63,625 | 0 | 122,694 | — | 0 | 186,319 |
| Skye DrynanIndependent · Audit (Chair) | 58,750 | 0 | 122,694 | — | 0 | 181,444 |
| Sandra Milligan, M.D., J.DIndependent · Compensation · Nominating/Governance (Chair) | 56,625 | 0 | 122,694 | — | 0 | 179,319 |
| John Quisel, Ph.D., J.DIndependent · Audit | 49,375 | 0 | 122,694 | — | 0 | 172,069 |
| Steven Nathan, M.DIndependent · Nominating/Governance | 44,750 | 0 | 122,694 | — | 0 | 167,444 |
| Faheem HasnainEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $350,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $350,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Gossamer Bio names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Gossamer Bio.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | RAPT Therapeutics | 2024 | Brian Wong | $630,000 | $0 | $5,927,297 | $416,000 | $6,979,539 |
| 2 | Allakos | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 3 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 4 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 5 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 6 | Poseida Therapeutics | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 7 | aTyr Pharma | 2025 | Sanjay Shukla | 638,977 | 0 | 2,595,200 | 210,862 | 3,456,253 |
| 8 | Atea Pharmaceuticals | 2025 | Jean-Pierre Sommadossi | 703,490 | 1,315,800 | 962,368 | 422,094 | 3,403,752 |
| 9 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 10 | Gossamer Bio | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 11 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 12 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 13 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| — | Fulcrum Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Mineralys Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Ventyx Biosciences | — | — | — | — | — | — | not in coverage universe |
| — | Annexon | — | — | — | — | — | — | not in coverage universe |
| — | Trevi Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Gossamer Bio | 65% | not disclosed | No | Alpine Rewards |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Allogene Therapeutics | 85% | Options 55 · RSU 25 · PSU 20 | No | Compensia |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Annexon | not disclosed | not disclosed | not disclosed | not disclosed |
| Atea Pharmaceuticals | not disclosed | not disclosed | No | Aon (Aon plc, Human Capital Solutions Practice) |
| aTyr Pharma | 60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)% | Options 100 | not disclosed | Radford (Aon plc Rewards Solutions) |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| Fulcrum Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Kodiak Sciences | 150% | Options 100 | not disclosed | Compensia, Inc. |
| Mersana Therapeutics | 85% | Options 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Mineralys Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Poseida Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| RAPT Therapeutics | 120% | Options 100 | not disclosed | Aon plc/Radford |
| Trevi Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Ventyx Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Faheem Hasnain | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Summary Compensation Table”. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568 |
| 2 | Section 01, Bryan Giraudo | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Summary Compensation Table”. As printed: 1,253,431. Filing ↗machine: r5 · c48 · span 385546–385555 |
| 3 | Section 01, Robert Smith | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Summary Compensation Table”. As printed: 1,180,744. Filing ↗machine: span 392612–392621 |
| 4 | Section 03, Robert Smith OPTION | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r8 · c13 · span 391387–391394 |
| 5 | Section 03, Bryan Giraudo OPTION | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r5 · c13 · span 384546–384553 |
| 6 | Section 03, Faheem Hasnain OPTION | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r2 · c13 · span 377176–377185 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-17 | 0001728117-26-000017 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Thomas Daniel, M.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 199,569. Filing ↗machine: t11 · r5 · c11 · span 196133–196140 |
| 9 | Section 08, Russell Cox | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 186,319. Filing ↗machine: t11 · r4 · c11 · span 194242–194249 |
| 10 | Section 08, Skye Drynan | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 181,444. Filing ↗machine: t11 · r3 · c11 · span 192384–192391 |
| 11 | Section 08, Sandra Milligan, M.D., J.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 179,319. Filing ↗machine: t11 · r6 · c10 · span 197646–197653 |
| 12 | Section 08, John Quisel, Ph.D., J.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 172,069. Filing ↗machine: t11 · r7 · c10 · span 199406–199413 |
| 13 | Section 08, Steven Nathan, M.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 167,444. Filing ↗machine: t11 · r2 · c11 · span 190775–190782 |
| 14 | Section 08, Faheem Hasnain | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, John D. Quisel 2026-06-04 | Form 4 | 2026-06-05 | 0001728117-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Skye Drynan 2026-06-04 | Form 4 | 2026-06-05 | 0002015102-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Thomas O. Daniel 2026-06-04 | Form 4 | 2026-06-05 | 0001538894-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Steven D. Nathan 2026-06-04 | Form 4 | 2026-06-05 | 0002015114-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Russell Cox 2026-06-04 | Form 4 | 2026-06-05 | 0001512984-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Sandra Milligan 2026-06-04 | Form 4 | 2026-06-05 | 0001859810-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 06, 2026 vote | Form 8-K | 2026-06-05 | 0001728117-26-000042 | Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 111,286,550). Filing ↗ |
| 22 | Section 06, 2025 vote | Form 8-K | 2025-06-25 | 0001728117-25-000043 | Item 5.07 · say-on-pay result. As reported: 97.08% (votes for as printed: 125,358,485). Filing ↗ |
| 23 | Section 06, 2024 vote | Form 8-K | 2024-06-10 | 0001728117-24-000069 | Item 5.07 · say-on-pay result. As reported: 74.19% (votes for as printed: 115,985,182). Filing ↗ |
| 24 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 25 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 26 | Section 09b board cost (computed) | Computed | — | computed | Cash 350,000 + equity 0 + all other 0 = 350,000, summed across the director compensation table rows.machine: formula: Σ = 350,000 |
| 27 | RAPT Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in RAPT Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 28 | Allakos, Section 10b CEO total | DEF 14A | 2024-04-23 | 0000950170-24-047043 | CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107 |
| 29 | Allogene Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 30 | AnaptysBio, Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 31 | Erasca, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187361 | CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533 |
| 32 | Poseida Therapeutics, Section 10b CEO total | DEF 14A | 2024-04-25 | 0000950170-24-048291 | CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164 |
| 33 | aTyr Pharma, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001339970-26-000021 | CEO total compensation as printed in aTyr Pharma's own proxy. As printed: 3,456,253. Filing ↗machine: t11 · r2 · c21 · span 533754–533763 |
| 34 | Atea Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182293 | CEO total compensation as printed in Atea Pharmaceuticals's own proxy. As printed: 3,403,752. Filing ↗machine: r3 · c22 · span 1526943–1526952 |
| 35 | Kodiak Sciences, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170429 | CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068 |
| 36 | Gossamer Bio (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001728117-26-000027 | CEO total compensation as printed in Gossamer Bio's own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568 |
| 37 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 38 | Mersana Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197 |
| 39 | Zentalis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001725160-26-000027 | CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357 |
| 40 | Section 10a, Allogene Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 41 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 42 | Section 10a, aTyr Pharma reciprocity | DEF 14A | — | 0001339970-26-000021 | aTyr Pharma names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 43 | Section 10a, Kodiak Sciences reciprocity | DEF 14A | — | 0001193125-26-170429 | Kodiak Sciences's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 44 | Section 10a, Mersana Therapeutics reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 45 | Section 10a, Allakos reciprocity | DEF 14A | — | 0000950170-24-047043 | Allakos's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 46 | Section 10a, AnaptysBio reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 47 | Section 10a, Atea Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-182293 | Atea Pharmaceuticals names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗ |